Tan et al. provided evidence that cholinesterase inhibitors and memantine were able to stabilize or slow the decline in cognition and function [135], with cholinesterase inhibitors showing a modest overall benefit for slowing behavioral decline and clinical global change in patients with AD. Here, BCHE is linked to Alzheimer disease.